|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cohen HT and McGovern FJ: Renal-cell
carcinoma. N Engl J Med. 353:2477–2490. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Fuhrman SA, Lasky LC and Limas C:
Prognostic significance of morphologic parameters in renal cell
carcinoma. Am J Surg Pathol. 6:655–663. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Edge SB and Compton CC: The American Joint
Committee on Cancer: The 7th edition of the AJCC cancer staging
manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Volpe A and Patard JJ: Prognostic factors
in renal cell carcinoma. World J Urol. 28:319–327. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hoffman AM and Cairns P: Epigenetics of
kidney cancer and bladder cancer. Epigenomics. 3:19–34. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chi P, Allis CD and Wang GG: Covalent
histone modifications-miswritten, misinterpreted and mis-erased in
human cancers. Nat Rev Cancer. 10:457–469. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yamaguchi H and Hung MC: Regulation and
Role of EZH2 in Cancer. Cancer Res Treat. 46:209–222. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Greer EL and Shi Y: Histone methylation: A
dynamic mark in health, disease and inheritance. Nat Rev Genet.
13:343–357. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liu L, Xu Z, Zhong L, Wang H, Jiang S,
Long Q, Xu J and Guo J: Enhancer of zeste homolog 2 (EZH2) promotes
tumour cell migration and invasion via epigenetic repression of
E-cadherin in renal cell carcinoma. BJU Int. 117:351–362. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Svotelis A, Bianco S, Madore J, Huppé G,
Nordell-Markovits A, Mes-Masson AM and Gévry N: H3K27 demethylation
by JMJD3 at a poised enhancer of anti-apoptotic gene BCL2
determines ERα ligand dependency. EMBO J. 30:3947–3961. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Xiang Y, Zhu Z, Han G, Lin H, Xu L and
Chen CD: JMJD3 is a histone H3K27 demethylase. Cell Res.
17:850–857. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ene CI, Edwards L, Riddick G, Baysan M,
Woolard K, Kotliarova S, Lai C, Belova G, Cam M, Walling J, et al:
Histone demethylase Jumonji D3 (JMJD3) as a tumor suppressor by
regulating p53 protein nuclear stabilization. PLoS One.
7:e514072012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shen Y, Guo X, Wang Y, Qiu W, Chang Y,
Zhang A and Duan X: Expression and significance of histone H3K27
demethylases in renal cell carcinoma. BMC Cancer. 12:4702012.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Leibovich BC, Blute ML, Cheville JC, Lohse
CM, Frank I, Kwon ED, Weaver AL, Parker AS and Zincke H: Prediction
of progression after radical nephrectomy for patients with clear
cell renal cell carcinoma: A stratification tool for prospective
clinical trials. Cancer. 97:1663–1671. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zisman A, Pantuck AJ, Dorey F, Said JW,
Shvarts O, Quintana D, Gitlitz BJ, deKernion JB, Figlin RA and
Belldegrun AS: Improved prognostication of renal cell carcinoma
using an integrated staging system. J Clin Oncol. 19:1649–1657.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Frank I, Blute ML, Cheville JC, Lohse CM,
Weaver AL and Zincke H: An outcome prediction model for patients
with clear cell renal cell carcinoma treated with radical
nephrectomy based on tumor stage, size, grade and necrosis: The
SSIGN score. J Urol. 168:2395–2400. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liu H, Xu J, Zhou L, Yun X, Chen L, Wang
S, Sun L, Wen Y and Gu J: Hepatitis B virus large surface antigen
promotes liver carcinogenesis by activating the Src/PI3K/Akt
pathway. Cancer Res. 71:7547–7557. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Budwit-Novotny DA, McCarty KS, Cox EB,
Soper JT, Mutch DG, Creasman WT, Flowers JL and McCarty KS Jr:
Immunohistochemical analyses of estrogen receptor in endometrial
adenocarcinoma using a monoclonal antibody. Cancer Res.
46:5419–5425. 1986.PubMed/NCBI
|
|
20
|
Camp RL, Dolled-Filhart M and Rimm DL:
X-tile: A new bio-informatics tool for biomarker assessment and
outcome-based cut-point optimization. Clin Cancer Res.
10:7252–7259. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zody MC, Garber M, Adams DJ, Sharpe T,
Harrow J, Lupski JR, Nicholson C, Searle SM, Wilming L, Young SK,
et al: DNA sequence of human chromosome 17 and analysis of
rearrangement in the human lineage. Nature. 440:1045–1049. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hong S, Cho YW, Yu LR, Yu H, Veenstra TD
and Ge K: Identification of JmjC domain-containing UTX and JMJD3 as
histone H3 lysine 27 demethylases. Proc Natl Acad Sci USA. 104:pp.
18439–18444. 2007; View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Agger K, Cloos PA, Rudkjaer L, Williams K,
Andersen G, Christensen J and Helin K: The H3K27me3 demethylase
JMJD3 contributes to the activation of the INK4A-ARF locus in
response to oncogene- and stress-induced senescence. Genes Dev.
23:1171–1176. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gerlinger M, Rowan AJ, Horswell S, Larkin
J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A,
Tarpey P, et al: Intratumor heterogeneity and branched evolution
revealed by multiregion sequencing. N Engl J Med. 366:883–892.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Aird KM and Zhang R: Nucleotide
metabolism, oncogene-induced senescence and cancer. Cancer Lett.
356:204–210. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sherr CJ: The INK4a/ARF network in tumour
suppression. Nat Rev Mol Cell Biol. 2:731–737. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Barradas M, Anderton E, Acosta JC, Li S,
Banito A, Rodriguez-Niedenführ M, Maertens G, Banck M, Zhou MM,
Walsh MJ, et al: Histone demethylase JMJD3 contributes to
epigenetic control of INK4a/ARF by oncogenic RAS. Genes Dev.
23:1177–1182. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kruidenier L, Chung CW, Cheng Z, Liddle J,
Che K, Joberty G, Bantscheff M, Bountra C, Bridges A, Diallo H, et
al: A selective jumonji H3K27 demethylase inhibitor modulates the
proinflammatory macrophage response. Nature. 488:404–408. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chen S and Shi Y: A new horizon for
epigenetic medicine? Cell Res. 23:326–328. 2013. View Article : Google Scholar : PubMed/NCBI
|
